Literature DB >> 34970772

Restricted survival benefit with right-censored data.

Shixiao Zhang1, Michael L LeBlanc1, Ying-Qi Zhao1.   

Abstract

The hazard ratio is widely used to quantify treatment effects. However, it may be difficult to interpret for patients and practitioners, especially when the hazard ratio is not constant over time. Alternative measures of the treatment effects have been proposed such as the difference of the restricted mean survival times, the difference in survival proportions at some fixed follow-up time, or the net chance of a longer survival. In this paper, we propose the restricted survival benefit (RSB), a quantity that can incorporate multiple useful measurements of treatment effects. Hence, it provides a framework for a comprehensive assessment of the treatment effects. We provide estimation and inference procedures for the RSB that accommodate censored survival outcomes, using methods of the inverse-probability-censoring-weighted U $U$ -statistic and the jackknife empirical likelihood. We conduct extensive simulation studies to examine the numerical performance of the proposed method, and we analyze data from a randomized Phase III clinical trial (SWOG S0777) using the proposed method.
© 2021 Wiley-VCH GmbH.

Entities:  

Keywords:  zzm321990 zzm321990 zzm321990 Uzzm321990 $U$zzm321990 zzm321990 zzm321990-statistic; inverse probability censoring weighting; jackknife empirical likelihood; restricted survival benefit

Mesh:

Year:  2021        PMID: 34970772      PMCID: PMC9162957          DOI: 10.1002/bimj.202000392

Source DB:  PubMed          Journal:  Biom J        ISSN: 0323-3847            Impact factor:   1.715


  16 in total

1.  Reformulating the hazard ratio to enhance communication with clinical investigators.

Authors:  Marc Buyse
Journal:  Clin Trials       Date:  2008       Impact factor: 2.486

2.  The Kaplan-Meier Estimator as an Inverse-Probability-of-Censoring Weighted Average.

Authors:  Glen A Satten; Somnath Datta
Journal:  Am Stat       Date:  2012-01-01       Impact factor: 8.710

3.  Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.

Authors:  Brian G M Durie; Antje Hoering; Muneer H Abidi; S Vincent Rajkumar; Joshua Epstein; Stephen P Kahanic; Mohan Thakuri; Frederic Reu; Christopher M Reynolds; Rachael Sexton; Robert Z Orlowski; Bart Barlogie; Angela Dispenzieri
Journal:  Lancet       Date:  2016-12-23       Impact factor: 79.321

4.  Efficiency of two sample tests via the restricted mean survival time for analyzing event time observations.

Authors:  Lu Tian; Haoda Fu; Stephen J Ruberg; Hajime Uno; Lee-Jen Wei
Journal:  Biometrics       Date:  2017-09-12       Impact factor: 2.571

5.  The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials.

Authors:  Julien Péron; Pascal Roy; Brice Ozenne; Laurent Roche; Marc Buyse
Journal:  JAMA Oncol       Date:  2016-07-01       Impact factor: 31.777

6.  On the restricted mean survival time curve in survival analysis.

Authors:  Lihui Zhao; Brian Claggett; Lu Tian; Hajime Uno; Marc A Pfeffer; Scott D Solomon; Lorenzo Trippa; L J Wei
Journal:  Biometrics       Date:  2015-08-24       Impact factor: 2.571

Review 7.  Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials.

Authors:  Ludovic Trinquart; Justine Jacot; Sarah C Conner; Raphaël Porcher
Journal:  J Clin Oncol       Date:  2016-02-16       Impact factor: 44.544

8.  Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.

Authors:  Kyongsun Pak; Hajime Uno; Dae Hyun Kim; Lu Tian; Robert C Kane; Masahiro Takeuchi; Haoda Fu; Brian Claggett; Lee-Jen Wei
Journal:  JAMA Oncol       Date:  2017-12-01       Impact factor: 31.777

Review 9.  Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better?

Authors:  Everardo D Saad; John R Zalcberg; Julien Péron; Elisabeth Coart; Tomasz Burzykowski; Marc Buyse
Journal:  J Natl Cancer Inst       Date:  2018-03-01       Impact factor: 13.506

10.  Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome.

Authors:  Patrick Royston; Mahesh K B Parmar
Journal:  BMC Med Res Methodol       Date:  2013-12-07       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.